Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients
Received 3 October 2018
Accepted for publication 27 March 2019
Published 6 May 2019 Volume 2019:12 Pages 601—611
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Steven F. Abcouwer
Mohamed Bakr Zaki,1 Ahmed Ibrahim Abulsoud,1,2 Ahmed Mohamed Elsisi,2,3 Ahmed Soliman Doghish,2,4 Ossama Abd Elmotaal Mansour,2 Ashraf Ismail Amin,5 Mahmoud Ahmed Elrebehy,4 Mohamed Yousef Mohamed,6 Mohamed Ahmed Goda6
1Biochemistry Department, Faculty of Pharmacy, Heliopolis University, El-Nahda, Cairo Governorate 11777, Egypt; 2Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 13465, Egypt; 3Biochemistry Department, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt; 4Biochemistry Department, Faculty of Pharmacy, Badr University in Cairo, Badr City, Cairo, Egypt; 5Department of Chemical and Clinical Pathology, National Institute of Diabetes and Endocrinology, Kasr El Ainy, Cairo, Egypt; 6Clinical Pharmacy Department, Faculty of Pharmacy (boys), Al-Azhar University, Nasr City, Cairo 13465, Egypt
Objective: This study aims to evaluate the expression pattern of circulating microRNAs (miR)-486-5p, miR-497, miR-509-5p, and miR-605 in the serum of metabolic syndrome (MetS) Egyptian male patients.
Methods: In this study, the circulating miR-486-5p, miR-497, miR509-5p, and miR-605 were amplified and quantitatively detected by quantitative real-time polymerase chain reaction in sera of 55 MetS male patients in comparison to 20 male controls. The level of fasting plasma glucose and triacylglycerol (TAG) were measured using calorimetric assay. Blood pressure was measured using mercuric sphygmomanometer. Anthropometric measurements were done to each individual. Furthermore, MetS patients were defined according to the criteria proposed by the American Heart Association and divided into three groups according to MetS index.
Results: The study was performed on three groups and a control group defined as follows: group 1: 15 MetS patients who fulfilled all diagnostic criteria of MetS; group 2: 20 MetS patients with normal blood pressure; group 3: 20 MetS patients with normal TAG levels.The levels of miRs are expressed as [median (IQR)]. miR-486-5-p and miR-497 expression were elevated in group 1 [31.9(49), p˂0.0001; 73.1(42.5), p˂0.0001], group 2 [36.4(15.7), p˂0.0001; 68.3(54.8), p˂0.0001], and group (3) [10.8(18.9), p=0.0014; 27.5(39.7), p=0.0012]. MiR-509-5p was elevated in groups 1 and 2 [501(468), p=0.0001], [309(436), p=0.0006], respectively, while normally expressed in group 3 [0.93(0.077), p=0.0001]. miR-605 was elevated in groups 1 and 3 [25.4(20.0), p=0.0018], [54.8(65.8), p˂0.0001], while normally expressed in group 2 [0.84(0.67), p˂0.0001].
Conclusion: miRs (486-5p, 497, 509-5p, and 605) serum levels were higher in MetS patients than in healthy control subjects; therefore, these serum miRs can serve as early biomarkers and can be used to follow-up the prognosis of MetS.
Keywords: metabolic syndrome (MetS), miR-486-5p, miR-497, miR509-5p, miR-605, metabolic syndrome index (MSI)
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]